

- abused drugs
  - addiction, 6, 52,74, 75
  - designer drugs, 51
  - effects on nervous system, **6,9, 51–53**, 71
  - health costs of, **20,53,232**
  - psychoactive drugs, 6, 10,27,44,50
  - withdrawal from, 74
  - see *also specific drugs*
- academic research
  - cooperative agreements with government, 94
  - factors influencing directions of, 92-94
- acetaldehyde, 297
- acetone, 14, 136,296, 297,303
- acetylcholine, 26, 66, 109, 124,294, 336
- acetylcholinesterase, 11,50,74,84,187,203, 289,290-292,336
- acetyethyl tetramethyl tetralin (AETT)
  - exposure route, 108
  - incidents of poisoning, 47, 54
  - neurological effects of, 54
- acrylamide, 73, 120
  - neurotoxicity testing, 166, 175
  - regulation for neurotoxicity, 178
  - risk assessment approaches, 150, 151,216
  - research on neurotoxicity, 258
- acrylates, 175
- acrylonitrile, 203
  - neurotoxicity testing, 166, 173
  - OSHA health standards, 185
- action levels for contaminants in foods, 164, 241–242, 336
- “Adam,” 51
- Administrative Procedure Act, 162
- age/aging
  - and exposure to neurotoxic substances, 269
  - as a factor in animal studies, 107
  - nervous system effects of, 8, 15, 54, 67, 152
  - and neurobehavioral tests, 126
  - and toxicity of chemicals, 15, 63, 152
  - see *also children; elderly*
- Agency for Toxic Substances and Disease Registry, 135–136
  - research activities of, 9, 11, 89, 188, 271, 322
- Agent Orange, 295
- Agricultural Pesticide Institute of the Philippines, 252
- air pollutants
  - hazardous, defined, 181
  - lead, 273–274, 276,281
  - standards for, 181, 182, 185
  - see *also Clean Air Act*
- Alar, 291
- Alaskan Marine Mammal Tissue Archival Project, 133
- alcohol and alcohol abuse, 4,44, 115
  - axonopathic effects, 73
  - effects on fetus, 70, 124
  - research on, 9, 11
  - thiamine deficiency and toxicity of, 71
- Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA), research
  - activities of, 33, 81, 88, 322
- aldicarb, 47, 173,251
- aldrin, 250,252,292
- allyl chloride, 303
- aluminum, 48
  - and Alzheimer’s disease, 54-55
  - oxide, 14, 136
- Alzheimer’s disease
  - effects on hippocampus, 71
  - environmental cause, 3, 6, 54-55, 70, 72
  - research on, 259
- American Academy of Pediatrics, 189
- American Conference of Governmental Industrial Hygienists, 28, 151, 185, 186,203,302-303
- American National Standards Institute, 185
- ammonia, 14, 136
- amphetamines, 74
- amyotrophic lateral sclerosis
  - characteristics of, 54
  - environmental cause, 3, 6, 54-55, 70, 72
  - incidence of, 54, 55
  - research on, 259
- anencephaly, 70
- anilines and substituted anilines, 179
- animal tests, 13
  - accuracy and reliability, 106, 115
  - advantages and limitations of, 105, 106, 111, 112, 114, 116, 120-121, 136, 137
  - alternatives to, 121–125; see *also in vitro neurotoxicity tests*
  - of BHMH, 55–56
  - biochemical markers, 117
  - choice of animals, 106-107, 109-110, 121, 152
  - in combination with in vitro tests, 13, 122, 124
  - cost factors, 106-107, 110, 222–225, 226,227
  - cross-species comparisons, 115–1 16, 121, 148
  - design, 105, 106-109,222
  - developmental neurotoxicology, 110, 111, 114-116, 137, 165-166, 178
  - dosing regimen, 107, 110, 147-148
  - comparability with human testing, 115
  - EPA guidelines, 110
  - evaluating chemicals for neurotoxicity, 109-110
  - extent and duration of exposure, 108, 222, 225, 226
  - extrapolation to humans, 18,82, 105, 121, 147, 148, 149, 153, 204
  - of food additives, 52
  - functional observational battery, 110,11 1–1 12,136,137,178, 224-225,226
  - hazard identification with, 147
  - housing conditions, 108-109
  - innovation impacts of, 226-227
  - longitudinal, 107
  - of MDMA, 51–52
  - motor activity, 110, 11 1–1 14, 136, 137, 178,224-225, 226
  - Motron Electronic Mobility Meter, 113
  - multispecies, 107

- neuropathological examination, 110, 111, 114, 136, 137, 178, 224-225, 226
- neurophysiology techniques, 118-121
- neurotoxic esterase assay, 111, 136-137, 178
- nutritional status of animals, 108
- observational methods, 112-113
- for organophosphorous pesticides, 110, 117-118
- quality assurance in, 222-223
- route of exposure, 108, 121, 222, 225
- schedule-controlled operant behavior, 110, 111, 116-117, 136, 137, 178, 224-225
- temperature of environment, 109
- tiered approach, 109-110
- types of, 110-121
- validation of, 109
- antagonism, 65
- antibiotics, 45, 70, 123, 125
- anticancer drugs, 51, 73
- antipsychotic drugs, 44, 50
- Apiol (with TOCP), incidents of poisoning, 47
- Argentina
- research on neurotoxicity, 258
  - use of banned pesticides in, 239
- arsenic, 133, 182, 183, 185
- aryl phosphates, 179
- asbestos, 176, 180, 182
- aspartame, 166, 198
- application process, 315-318
  - claims of adverse effects, 18, 318-319
  - postmarketing surveillance, 318
- aspartate, 71
- Association of People for Practical Life Education, 252
- astrocytes, 117
- attentional disorders, 70, 229, 273
- auditory system
- substances affecting, 49, 119, 131, 135, 272
  - testing of, 119
- Australia, use of banned pesticides in, 239
- axonopathy
- causative agents, 73-74
  - defined, 67, 336
- axons, 72
- development of, 67
  - effects of toxic substances on, 67, 69, 73, 295
  - functions of, 65-66, 336
- azidothymidine, 167
- barium, 183
- Basic Document on Regulations of Registration, Marketing and Control of Agricultural Chemicals for Countries of Central America, 253-254
- Bayley Scales of Infant Development, Mental Development Index, 155
- behavioral effects, 70
- Collaborative Behavioral Teratology Study, 115
  - defined in TSCA, 174
  - duration of exposure and, 70
  - EPA research on, 82
  - examples of, 46
  - of lead, 46, 229-230, 272, 273
  - of organic solvents, 298-299
  - of pesticide poisoning, 285
  - research needs on, 154
  - tests for, see neurobehavioral tests
  - see *also* operant behavior
- behavioral teratology, 70, 114-116
- Belgium, regulatory policies in, 246-247
- Benton Visual Retention Test, 127
- benzene, 14, 135, 136, 182, 297, 303
- beryllium, 182
- BHC, 252
- BHMH, incidents of poisoning, 47, 55-56
- biochemical markers, 11, 82, 84, 117
- biological monitoring, 133-134
- blood-brain barrier
- drug passage through, 66-67
  - fetal, 70
  - structure and function, 336, 66-67, 73
- blood vessels, neurotoxic substances acting on, 74, 76
- botulinum toxin, 45
- Bourdon Wiersma Vigilance Test, 127
- brain
- aging, and structure of, 15, 67, 152
  - congressional resolution on Decade of the Brain, 330-331
  - development of, 67
  - opioid receptors, 74
  - regional differences in sensitivity to toxic substances, 68
  - structure and function, 66
- brain damage
- from abused drugs, 51, 70
  - from lead, 271
  - from mercury, 131
  - from pesticides, 291
- brainstem auditory evoked responses, 119, 128
- Brazil, pesticide misuse in, 251
- buckthorn (*Karwinskia humboldtiana*), 74
- B-bungarotoxin, 124
- Bureau of Community Environmental Management, 277
- n-butyl alcohol, 14, 136
- cadmium, 48, 68, 74
- monitoring of, 133, 134
  - research on, 257
- California Birth Defects Prevention Act of 1984, 289-290
- camphechlor, 250
- Canada
- human tissue monitoring, 132
  - regulatory policies and practices in, 245
  - research on neurotoxicity, 258
- carbamate insecticides, 26, 49, 74, 175, 287, 289-291, 293, 295, 336
- carbon disulfide
- exposure limits for, 187, 303
  - neurological effects of, 73, 108, 298, 299
  - poisoning incidents, 256
  - releases, 14, 136
- carbon monoxide
- air quality standards, 181, 182
  - central nervous system effects, 181, 187
  - poisoning, 64, 69, 181
  - research on neurotoxicity, 258
- carbon tetrachloride, 297
- carbonyl sulfide, 14, 136
- carcinogenicity, 56

- cassava (*Manihot esculenta*), 55
- cell cultures  
 defined, 123,336  
 mixed, 338  
 monolayer, 124  
 muscle cells, 124  
 retinal neurons, 124
- cell lines, 124, 125, 336
- Center for Environmental Health, research activities of, 90-91
- Center for Science in the Public Interest, 192
- Centers for Disease Control  
 acceptable levels for lead, 271  
 human monitoring program, 133  
 lead poisoning prevention program, 277  
 research activities of, 9, 11, 12, 81, 322
- central distal axonopathy, 74
- central nervous system, 336  
 degeneration, 72  
 depression of activity, 108  
 lead effects on, 272  
 pesticide effects on, 284-285  
 structure, 66
- central-peripheral distal axonopathy, 67, 73-74
- cerebellum, 67, 70, 72, 336
- cerebral palsy, 49
- cerebrum, 70, 336
- charitable organizations, research by, 97
- Chemical Industry Institute of Toxicology, 123-124
- Chemical Specialties Manufacturing Association, 220
- chemicals  
 commercial, see industrial chemicals  
 consumer, 17  
 diversity of new products, 227  
 high production, high exposure, 17, 178-179, 195, 197,202, 204,227  
 licensing and registration of, 174-180, 197,202  
 low production, low exposure, 178,227-228  
 neurotoxic, classes of, 175  
 neurotoxicity tests and innovation in, 227-228  
 new v. existing, consistency of regulation, 17, 18, 196-198  
 patent protection, 226  
 premanufacture notices, 17, 174-176, 194, 196, 197, 201-202,219-220,227,247  
 priorities for testing, 178  
 reporting of harmful effects of, 180, 197  
 significant new use rule, 174  
 subject to neurotoxicity evaluation under TSCA, 179, 202  
 testing of, 174-175, 232  
 see *also* neurotoxic substances; organic solvents; *and specific chemicals*
- chemoreceptors, 65
- children  
 lead poisoning in, 7,8,46,70,72-73,181, 229,267,268-271, 273,275,278  
 mental disorders in, 8, 45, 70, 73  
 number exposed to lead, 269, 271  
 pesticide risks to, 25,283,284,293,295  
 vulnerability to neurotoxic substances, 8, 45, 267, 268, 283
- chlordane, 238-239, 250, 252, 292
- chlordecone, incidents of poisoning, 47, 50, 293
- chlordimeform, 120, 250
- chlorine, 14, 136
- chlorofluorocarbons, neurotoxicity testing, 166
- chloroform, 14, 136, 303
- chloroquine, 124
- chlorophenoxy herbicides, 294-295
- cholinesterase inhibitors, see acetylcholinesterase; organophosphorous pesticides
- chromium, 133
- Clean Air Act, 135  
 1970 amendments, 180  
 amendments proposed, 26, 182, 280  
 cost-benefit analysis under, 216  
 definition of hazardous air pollutant, 181  
 lead regulation under, 273  
 regulatory authority, 23, 160, 162  
 risk assessment approach, 160  
 standard setting under, 180-182  
 toxic substances regulated by, 160
- Clean Water Act, 26  
 regulatory authority, 16, 23, 160  
 risk assessment approach, 160  
 standard setting under, 180, 182-183, 187  
 toxic substances regulated by, 160
- clioquinol, incidents of poisoning, 47, 74
- cocaine, 9, 44, 115  
 effects on nervous system, 6, 52, 74-75  
 fetal effects of, 10,53,70,74
- Codex Alimentarius Commission, 242
- cognitive effects  
 of carbon monoxide poisoning, 181  
 detection of, 70  
 examples of, 46  
 of lead poisoning, 44, 70, 181, 269,273  
 of pesticide poisoning, 285
- Cognitive Scanner, 128
- Colombia, use of banned pesticides in, 239,243
- Color Additive Amendments of 1960, 165
- color additives, see food and color additives
- Comprehensive Drug Abuse Prevention and Control Act, 188
- Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), 26, 198  
 control measures under, 187-188, 280-281  
 regulatory authority, 16, 23, 161  
 risk assessment approach, 161  
 toxic substances regulated by, 161,280-281  
 see *also* Superfund Amendments and Reauthorization Act
- computer-based testing, 127-128, 137
- confidentiality, trade secret protection and testing, 19, 25, 176, 202,218,226,288
- Consumer Product Safety Act (CPSA), 172  
 regulatory authority, 16, 160  
 reporting requirements for adverse effects, 204  
 risk assessment approach, 160  
 standard setting under, 180, 184  
 toxic substances regulated by, 160
- Consumer Product Safety Commission (CPSC), 176  
 in vitro testing by, 122  
 policy issues and options for, 31  
 regulatory authority of, 160, 161, 184, 190, 191, 268  
 research activities of, 323  
 risk assessment applications, 150  
 standard setting by, 184, 276
- Consumers Association of Penang, 252

- control-oriented measures
  - under CERCLA, 187–188
  - under Controlled Substances Act, 188
  - economic incentives, 161
  - features of laws, 159, 161
  - under bad-Based Paint Poisoning Prevention Act, 189–191
  - under Marine Protection, Research, and Sanctuaries Act, 188-189
  - under Poison Prevention Packaging Act, 189–191
  - regulatory approach, 16, 159
  - under Resource Conservation and Recovery Act, 191
- Controlled Substances Act
  - control measures under, 187, 188
  - regulatory authority, 16, 161
  - risk assessment approach, 161
  - toxic substances regulated by, 161
- cosmetics
  - antidandruff shampoos, 108
  - color additives in, 165
  - dermal exposure to toxic substances, 108
  - fragrances, 108
  - incidents of neurobehavioral toxicity, 54
  - licensing and registration of, 168
  - regulation of, 54
  - testing, 17,28, 52,54, 168, 196
- cost-benefit analysis
  - competing interests in, 56
  - costs defined, 214, 215
  - defined, 336
  - economic principles of, 221
  - effect on environmental policymaking, 220-221
  - Executive Order 12291 requirements, 212,214-216,220,231
  - under FIFRA, 216, 286
  - health costs in, 228–230
  - knowledge requirements for estimating benefits, 228
  - for lead, 216
  - net efficiency, 215, 338
  - risk reduction, measures of, 215
  - in standard setting, 181
  - under TSCA, 216
  - unit of value in, 221
- cost-effectiveness analysis, 214,220, 221,336
- Costa Rica regulatory issues in, 253-254
- costs of testing
  - in animal studies, 20, 106-107, 110, 111, 112, 116, 222–225
  - drug and pesticide development and, 225–227
  - estimates of, 20, 224-225,231
  - fees, 223
  - financial determinants, 106,223-224
  - general and administrative rates, 223
  - in vitro methodologies, 122
  - and innovation, 217–218, 225–228
  - labor rates, 222,223-224
  - laboratory automation and, 116,223
  - laboratory capabilities and, 223
  - overhead rates, 223
  - personnel, 223
  - protocol and, 222
  - quality assurance, 222-223
  - reregistration of pesticides, 241
  - scientific determinants, 222–223
  - under TSCA, 217
    - unit test costs, 217 n.10
- Council on Environmental Quality, 177
- cresols, 179, 303
- cumene, 179
- cutaneous receptors, 65
- cyanide, 55
- cycad, 54, 74
- cyclamates, 166
- cyclohexane, 179,297
- cyclohexanone, 179
- 2,4-D, 183,294,295
- DDT, 50,72, 134,250,252,255,292
- deltramethrin, 251
- dementia, 229,259,299,336
- dendrites, 72
  - development of, 67
  - functions of, 65-66, 336
- Department of Agriculture
  - monitoring programs, 135
  - regulatory authority of, 160, 161, 171, 241, 242
  - research activities, 9, 11, 81, 92
- Department of Commerce, 177
- Department of Defense, research activities of, 90,324
- Department of Energy, research activities of, 9, 11,81,91,323
- Department of Health and Human Services, 8,45
  - human research regulations, 130
  - neurotoxicology -related activities, 321
- Department of Housing and Urban Development, 276
- Department of Justice, regulatory authority of, 161, 188
- Department of Labor, research activities of, 323–324
- Deprenyl, 6,72
- designer drugs, 51
- detoxification systems, in humans, 44,45,64
- developing counties
  - famine in, 243,245
  - imports of pesticides, 237, 242
  - manufacture of banned or restricted pesticides in, 243, 253, 255
  - pesticide misuse in, 50,239,248-249,253
  - poisonings and deaths from pesticides in, 250-251,260,283
  - regulatory issues in, 21–22, 237–238, 248–256, 2260
  - screening test for, 126
  - susceptibility to neurotoxicity in, 71
  - use of pesticides, 250, 260
  - see also *specific countries*
- developmental neurotoxicity, 110, 111
  - animal tests for, 13, 114–1 16, 137, 165-166, 247–248, 336
  - biochemical markers, 117
  - of pesticides, 172
  - testing guidelines, 153, 165–166, 178, 179, 192,248
- di-tert-butylphenyl phosphite, 166
- 1,2-dibromo-3-chloropropane, 185,250
- dichloromethane, 14, 136
- 1,2-dichloropropane, 179
- dichloropropene, incidents of poisoning, 47
- dichlorvos, 173
- dieldrin, 250,252,292
- N,N-diethyl-m-toluamide, 172
- diethylene glycol butyl ethers, testing guidelines, 115, 179
- diisodecyl phenyl phosphite, 179
- Dimecron, 284

- dioxin, 180,294
- diphenylhydantoin, 115
- diphtheria toxin, 74
- Dominican Republic, use of banned pesticides in, 239
- domoic acid, incidents of poisoning, 47
- dopamine, 66,72,336
  - depletion of, 6, 109
  - effects of cocaine on, 52,74
- dose
  - acceptable daily intake, 148, 336
  - behaviorally effective, 116
  - defined, 337
  - extrapolation from high to low, 148, 154, 200
  - reference (RfD), 116, 148–149, 150, 153, 340
  - regimen in animal tests, 107, 110
  - threshold, 14, 147, 151, 153, 162, 185,203,341
  - and toxicity, 6, 44, 70, 108, 150, 283, 290
  - see *also* no observed adverse effect levels; no observed effect levels
- dose-response assessment
  - from automated motor activity measures, 113
  - defined, 63,337
  - extrapolation of doses, 147
  - issues in, 107, 153–154
  - methods, 111, 118, 147–148
  - NOAEL versus NOEL, 147–148, 153
  - in risk assessment, 147–148
  - safety factors, 147, 148, 149, 153–154, 155
  - thresholds and RfD approach, 153, 155
- Down's syndrome, 71
- doxorubicin, 73
- drinking water
  - hazardous wastes in, 198
  - lead in, 216,230,269,277–279
  - regulations to control contaminants, 183–184, 216, 277–279
  - from water coolers, 279,280
- Drug Price Competition and Patent Restoration Act, 226
- drugs
  - axonopathy from, 73
  - color additives in, 165
  - development, 219,225–226,231–232
  - neurotoxic potential, 43
  - neurotoxicity testing and innovation in, 226–227
  - passage through blood-brain barrier, 67
  - see *also* abused drugs; therapeutic drugs; *and specific drugs*
- economic issues, 56
  - analysis of regulations, 213–221, 230
  - benefits of regulating neurotoxic substances, 20, 228–231, 232
  - cost-benefit analyses, 20,211, 214–215,220–221, 337
  - cost-effectiveness analyses, 214–215, 220, 221, 337
  - in design of animal experiments, 106, 222–223
  - economic efficiency, 56, 214–216
  - innovation incentives and disincentives, 20, 218–220, 225–228
  - market prices and profitability and costs of regulation, 217–218
  - opportunity costs, 221, 228
  - regulatory analyses, 20,211, 214–215,218 n.11, 220–221
  - regulatory impact analyses, 211, 214, 231
  - risk assessments, 211, 231
  - risk-benefit analyses, 20, 211, 216–217, 218 n.11, 340
  - in standard setting, 199
  - see *also* costs of testing; health costs of neurotoxicity; risk assessment
- “ecstasy,” 9, 51
- Ecuador
  - pesticide import problems, 243
  - regulatory issues in, 255–256
- education
  - of health-care professionals, 97–100
  - of research scientists, 97, 259
  - of workers, 30, 287
- Egg Products Inspection Act, 241,242
- elderly, vulnerability to neurotoxic substances, 8, 45
- electroencephalograph, 119
- electromyography, 128, 337
- electroneurography, 128, 337
- electrophysiological testing, 82, 337
  - electroencephalograph, 119
  - macroelectrode, 118
  - microelectrode, 118
  - multiunit electrode, 118
  - of muscle cells, 124
- encephalitis, 74
- encephalopathy, 74, 181, 337
- endorphin, 66, 74
- endpoints, 337
  - for emission standards for hazardous air pollutants, 182
  - in risk assessment, 15, 149, 150, 151, 152, 153
  - for toxicity testing, 109, 116, 125, 150, 152, 178
  - for water quality criteria, 182–183
- endrin, 47, 183, 250, 255, 292
- enkephalin, 66, 74
- environmental hypothesis, 54–55, 70, 72, 337
- Environmental Protection Agency (EPA), 56, 177
  - Clean Air Scientific Advisory Committee, 271
  - coordination of regulatory efforts within, 191–192, 198
  - core test battery, 13,20, 23–24, 110–111, 114, 137, 152, 178, 179,224,231,287
  - definition of neurotoxicity, 44
  - developmental neurotoxicology workshop, 115
  - economic assessment of regulations, 213, 218
  - health advisories, 183–184
  - impact analysis of regulations, 220–221
  - Integrated Risk Information System, 198
  - labeling criteria, 172
  - monitoring activities, 132, 133
  - Neurotoxicology Division, 81–84
  - Office of Drinking Water, 183
  - Office of Environment Criteria and Assessment, 187
  - Office of Mobile Sources, 182
  - Office of Pesticide Programs, 110, 135, 170–172, 191–192, 203,216,287
  - Office of Program Planning and Evaluation, 198
  - Office of Solid Waste Management, 198
  - Office of Toxic Substances, 110,152,174,176,177, 191–194, 197, 198,200,201,216
  - Office of Water Regulations and Standards, 182
  - pesticides registered with, 49
  - policy issues and options relevant to, 23–27,31–32
  - policy on neurotoxicity testing, 178
  - regulatory authority of, 15–16, 26, 23, 160–162, 164,

- 170-177,179-182,187, 189,197,212,227 n. 16,241,267  
 research activities, 9, 11, 31-32, 81-84, 323  
 Risk Assessment Forum, 11  
 risk assessment guidelines, 116, 146, 150, 192, 216  
 Science Advisory Board, 81,82,84  
 Scientific Advisory Panel, 110-111, 115, 173,288  
 standard setting, 180-183  
 testing guidelines, 13,110-112,114-118, 136,137, 177-179,  
 191-193,200,201,222, 287  
 Tolerance Assessment System, 135  
 Toxics Release Inventory, 3,43, 122, 134-136, 195
- epidemiological studies, 337  
 advantages and limitations of, 125, 128  
 computer-based neurobehavioral tests for, 127  
 geographical isolates of neurological conditions, 259  
 hazard identification with, 147  
 industry-government cooperation on, 96  
 international activities in, 259  
 need for, 55, 154  
 occupational, 129-120  
 of pesticide poisoning, 285, 295  
 specimen banking for, 132
- erythrosin, 166  
 ethanol, see alcohol and alcohol abuse  
 ethical issues  
 exports of toxic substances, 56-57, 243, 245, 261  
 human testing and monitoring, 125, 130, 136  
 manufacturers' duty to follow products to consumers, 249
- Ethiopia  
 lathyrism in, 55  
 research on grass pea neurotoxicity, 259
- ethyl acetate, 297  
 ethyl ether, 297  
 ethyl nitrate, 297  
 ethyl parathion, 250, 251  
 ethyl toluenes, 179  
 ethylene, 14, 136  
 ethylene dibromide, 250  
 ethylene dichloride, 303  
 ethylene glycol, 297  
 ethylene oxide, 185  
 ethyl-p-nitrophenyl phosphonothionate, 203  
 risk assessment approaches, 150, 151, 173
- European Economic Community, testing guidelines, 115
- evoked potentials, 337  
 brainstem auditory, 119  
 flash, 119  
 pattern reversal, 119  
 somatosensory, 118-1 19, 120-121  
 visual, 119-120
- excitotoxicity, 71
- Executive Order 12264, control of exports of hazardous  
 substances, 57, 240-241, 260
- Executive Order 12291  
 cost-benefit analyses under, 212, 215-216, 220  
 inflation considerations in, 217 n.9  
 requirements of, 213-214
- exports of toxic substances  
 consent requirements, 240  
 Executive Order 12264,57,240-241  
 famine as justification for, 243,245,261  
 international effects of U.S. practices, 21-22, 242-245
- labeling violations, 242-243  
 notification requirements, 22, 239-240, 247, 261, 339  
 pesticides, 56-57,237, 241-245, 249-250, 261  
 repackaging problems, 243  
 testing requirements, 240  
 U.S. laws, 239-241,261
- exposure to neurotoxic substances  
 acute, 26, 108, 111, 114, 116, 125, 148, 222, 224,272, 292,  
 294,296,336  
 additive effects, 44  
 in animal tests, 107-108  
 assessment of, 132, 148; see also Monitoring of toxic  
 substances  
 chronic, 26,44, 114, 116, 125; 148, 152,222,224,256,257,  
 272,291,294,296,336  
 defined, 337  
 dermal, 107, 108,292-293,294-295, 296,298  
 extent and duration, 4,44,67-68,73, 107, 108,125, 133,148,  
 152,222,337  
 human studies of, 128-131  
 inhalation, 107, 108, 269, 292,293, 296, 298  
 margin of (MOE), 149  
 oral, 107, 269, 292, 298  
 OSHA limits for mercury, 131  
 pattern of, 148, 178, 339  
 prevention of, 130-131  
 risk to humans, 43  
 routes of, 6, 63, 64, 107-108, 121, 125, 131, 148, 222, 224,  
 231,269,283,290,293, 298,340  
 subacute, 108  
 subchronic, 108, 111, 114, 148, 149, 340  
 see also dose; occupational exposures; and specific  
 substances
- Eysenck Personality Inventory, 127
- famine, and pesticide use, 243,245,253,261
- Faroe Islands, 259
- Federal Emergency Planning and Community Right-to-Know  
 Act of 1986, 13, 134
- Federal Environmental Pesticide Control Act, 170,213
- Federal Food, Drug, and Cosmetic Act (FFDCA), 56, 172,213  
 1962 amendments, 217,219  
 amendments proposed, 168  
 color additive regulation, 164-166  
 cosmetics regulation, 17, 168  
 Delaney clause, 17, 195  
 drug review and regulatory process, 16, 29, 51, 166-169,  
 221-222  
 economic balancing provisions of, 212  
 environmental contaminants of food, 163-164  
 food additive regulation, 52, 164-166  
 licensing and registration under, 27,29, 161, 163-169  
 notification requirements, 218  
 pesticide residue standards, 164,241  
 regulatory authority, 16, 160, 213  
 reporting requirements for adverse reactions, 167,203  
 risk assessment approach, 160  
 risk-benefit analysis under, 216  
 tolerance setting, 216  
 toxic substances regulated by, 160
- Federal Hazardous Substances Act, 172  
 definition of hazardous substance, 184

- regulatory authority, 16, 160
- risk assessment approach, 160
- standard setting under, 180, 184
- toxic substances regulated by, 160, 190
- Federal Insecticide Act, 168
- Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), 56, 172,213
  - 1972 amendments, 170,219,285-286
  - 1988 amendments, 18, 171, 192, 197,217, 287,288
  - amendments proposed, 24, 26
  - coordination of TSCA neurotoxicity evaluations with, 191–192
  - definition of pesticide, 281-282
  - economic balancing provisions of, 212,216, 286
  - export controls, 21–22, 239, 240,261
  - extent of testing under, 17, 18, 24, 203, 221–222, 287
  - generic testing guidelines, 115, 136, 171, 192
  - licensing and registration under, 17, 16, 29, 161, 169-173, 194, 199,201,203,204
  - new pesticide registration, 17, 164, 170-171, 194
  - notification requirements, 218, 238, 240
  - pesticide residues in food, 241
  - protection of workers under, 285-287
  - regulatory authority, 16, 23, 26, 160
  - reregistration of existing pesticides, 17, 171–173, 286, 287
  - risk assessment approach, 160
  - risk-benefit analysis under, 216, 286
  - Science Advisory Panel, 192
  - tolerance setting, 27, 164
  - toxic substances regulated by, 160
- Federal Interagency Hazardous Substances Export Policy Task Force, 57
- Federal Meat Inspection Act, 241,242
- Federal Mine Safety and Health Act
  - regulatory authority, 16, 161
  - risk assessment approach, 161
  - standard setting under, 180, 185, 186
  - toxic substances regulated by, 161
- Federal Republic of Germany
  - human tissue monitoring, 132
  - neurotoxicity testing approach, 24
  - regulatory policies in, 22, 245–246, 260,261
  - researcher mining, 259
- Federal Water Pollution Control Act
  - regulatory authority, 16, 23, 160
  - risk assessment approach, 160
  - standard setting under, 180, 182–183
  - toxic substances regulated by, 160
- Federation of American Societies for Experimental Biology, testing recommendations of, 114, 193
- fenvalerate, 113
- fetuses
  - alcohol effects, 70, 124
  - antibiotic effects, 70
  - cocaine effects, 9, 10, 52, 53, 70, 74
  - lead effects, 272
  - nervous system development, 67
  - mercury poisoning, 49, 152
  - steroid effects, 70
  - therapeutic drug effects, 51,73
  - vulnerability to neurotoxic substances, 8, 45, 49, 70, 269
- Finland, Institute of Occupational Health neurotoxicity test, 126
- flash evoked potentials, 119, 128
- food
  - action levels for contaminants in, 164
  - adulterants, 241
  - imports, 239, 241–242, 250
  - lead in, 274-275
  - pesticide residues in, 241-242,250,260
  - regulation of environmental contaminants of, 163–164
- Food Additives Amendment of 1954, 164
- food and color additives
  - adverse effects claims, 318
  - appeals of decisions, 31&317
  - application, 315
  - approval process, 315–3 19
  - lead in, 275
  - licensing and registration process, 52, 164-166
  - postmarketing surveillance, 318
  - preapplication, 315
  - regulation of, 17, 52, 161, 195, 204
  - review, 203, 315
  - testing for neurotoxicity, 18,27,52, 166, 199,204
- Food and Drug Administration (FDA), 56
  - analytical methods for pesticide detection, 50
  - Center for Biologics Evaluation and Research, 167
  - Center for Drug Evaluation and Research, 167,168, 198,201
  - Center for Food Safety and Applied Nutrition, 12, 165-166, 192–194
  - color additive regulation, 192–194
  - cosmetic regulation, 54
  - drug review and regulatory process, 51, 199
  - economic assessment of regulations, 213
  - food additive regulation, 52, 192-194
  - interpretation of safety, 165
  - monitoring system for adverse drug reactions, 29, 168, 169, 198
  - neurotoxicity testing by, 27, 166
  - policy options for, 27-28,33-34
  - Priority-Based Assessment of Food Additives Program, 198
  - Red Book for food and color additives, 27–28, 166-167, 192-194,340
  - regulatory authority of, 15–16, 54, 160, 161, 163–167, 171, 188,200,241-242,267
  - research activities of, 9, 12, 33–34, 81, 88-89, 122, 323
  - risk assessment applications, 150
  - testing guidelines, 27, 51, 167–168, 192–194, 199-200,204
  - Total Diet Study, 135
- Food and Drugs Act of 1906, 163
- Food Safety Amendments of 1989, 168
- France
  - regulatory policies in, 247, 259
  - research on neurotoxicity, 258
- Freon 12, 166
- Freon 113, 14, 136
- furfuryl alcohol, 303
- fumigants, neurotoxic, 293-294
- functional observational battery
  - advantages and limitations, 11 1–112
  - costs of, 20, 224-225, 226, 231
  - defined, 337
  - in EPA core test battery, 13, 111, 136, 204
  - EPA guidelines for, 110, 111, 178
  - FDA approach, 193

- OECD guidelines, 194  
fungicides, mercury, 48,257
- Galecron, 250  
Gammalin 20,252  
ganglion, 124, 337  
General Accounting Office, 220  
Generally regarded as safe (GRAS) compounds, 27  
Ghana  
  Lake Ghana pesticide poisoning incident, 252  
  regulatory issues in, 248  
Ginger-Jake syndrome, 47,69  
glial cells  
  development of, 67  
  effects of toxic substances on, 67  
  function of, 65, 124,337,339  
  neurotoxic substances acting on, 74  
glial fibrillary acidic protein (GFAP) radioimmunoassay, 117  
Global Environment Monitoring System, 134  
glue-sniffing, 48; see *also* inhalant abuse  
glutamate, 71, 124  
glycol ethers  
  releases of, 14, 136  
  toxicity of, 175  
  testing of, 115, 135  
grass pea, 55,259  
Guam ALS-Parkinson's dementia, 54,70,74,259
- Halcion, FDA monitoring of adverse reactions to, 29, 169  
hazard identification, 147, 152, 154  
hazardous wastes  
  defined, 187, 191  
  in drinking water, 198  
  registry of persons exposed to, 135–136  
health-care professionals  
  education of, 97-100  
  see *also* nurses; industrial hygienists; physicians  
health costs of neurotoxicity  
  dementia, 229  
  of drug abuse, 20, 53  
  exposure to lead, 20, 229–230  
  mental disorders and nervous system diseases, 229  
  personal health-care expenditures, 20-21,229  
health effects  
  “adverse” defined, 7, 4445, 115–1 16, 145, 162, 167, 170, 212,228  
  delayed, 50,54,70, 107, 117, 118, 151-152, 155, 194  
  “harmful,” 145, 147  
  nutritional status and, 70, 72  
  reversibility of, 15,46, 69, 71, 107, 108, 151, 152, 290  
  secondary, 45, 72  
health status, and neurotoxicity, 8,70-71, 108,290  
heavy metals  
  assessment of effects of, 119, 124  
  effects on nervous system, 74  
  monitoring of, 135  
  research on, 256, 258  
  toxicity of, 46, 71; see *also specific metals*  
hen test, see neurotoxic esterase assay  
heptachlor, 238,250,292  
heroin, 6,9,44,72,74  
hexachlorobenzene  
  effect on nervous system, 74  
  incidents of poisoning, 47  
hexachlorocyclohexane, 250  
hexachlorophene, 45  
n-hexane, 73, 124, 297, 299  
  incidents of poisoning, 47  
  neurotoxicity testing, 179  
  regulation of, 184  
  risk assessment approaches, 150, 151  
2,5-hexanediol, 124  
hippocampus  
  functions and structure of, 68,71  
  PCP effects on, 71  
  trimethyltin damage to, 68, 74  
Hispanic Health and Nutrition Examination Survey, 132  
Honduras, pesticide-contaminated exports, 238-239  
Human Nutrition Information Service, 135  
human testing and studies, 105,336  
  computerized techniques, 13, 127–128, 137  
  confidentiality, 130  
  consent and disclosure requirements, 130  
  examiner-subject interaction, 128-129  
  exposure studies, 128–131, 256  
  extrapolation of results to other populations, 147, 153  
  of food additives, 52  
  Institutional Review Boards, 130  
  for lead exposure, 270  
  legal and ethical considerations, 12, 125, 130  
  limitations of, 147  
  neurobehavioral, 13, 125–126, 137  
  neurophysiological techniques, 13, 128, 137  
  selection of study populations, 105, 129  
  of therapeutic drugs, 52  
  types of, 125-128, 137  
  workplace research, 129  
  see *also* epidemiological studies  
hydrocarbons, 182  
hydrochloric acid, 14, 136  
hydroquinone, 179
- imidazoles, 175  
imports  
  and “circle of poison,” 22,57,238,250,260,261  
  controls in developing countries, 250-255  
  see *also* exports of toxic substances  
in vitro tests, 338  
  advantages and limitations of, 12–13, 56, 105, 118, 122, 124-125, 136  
  application to neurotoxicity testing, 122, 123–124  
  cell lines, 124  
  costs of, 122  
  development of, 11, 12-13, 84, 122, 137  
  primary cultures, 123-124  
  screening with, 13, 110  
  validation of, 123–124  
  see *also* tissue culture, 122, 123  
incinerator ash  
  exports of, 240  
  lead in, 268,279-280  
India  
  Bhopal accident, 243  
  grain surpluses, 243



- regulatory activities in, 253
- research on neurotoxicity, 258
- Indonesia, pesticide misuse in, 251
- industrial chemicals
  - axonopathy from, 73
  - incidents of poisoning, 47,48-49
  - licensing and registration of, 16,161,174-180,195,196, 204;
    - see *also* Toxic Substances Control Act
  - neurotoxic potential, 3,43, 48,259
  - see *also* chemicals; organic solvents; *and specific chemicals*
- industrial hygienists, education of, 99
- industrial research, 12
  - by consumer product industry, 95
  - government-industry consortia, 96
  - industry consortia 96
  - by pesticide industry, 94
  - by pharmaceutical industry, 95
- industrialized countries
  - imports of contaminated food, 238
  - regulatory policies in, 245–248, 260
  - see *also specific countries*
- inert ingredients, neurotoxicity evaluations, 24,288
- inhalant abuse, 48, 49, 296, 299-300
- innovation
  - chemical R&D, 219–220, 227–228
  - costs of neurotoxicity testing and, 225–228
  - drug R&D, 219,225-226
  - input measures, 219
  - output measures, 219
  - pesticide R&D, 219,226-227
  - regulation and incentives for, 20, 218–220
- integrated pest management, 243, 290, 291, 295, 337
- Inter-American Institute for Cooperation on Agriculture, 253-254
- interaction of toxic substances
  - additive effects, 44, 64
  - antagonism, 65
  - drugs, 8-9,29,45, 169
  - potentiation, 65
  - synergistic effects, 64, 65
  - sources of complex mixtures, 65
- Interagency Testing Committee, 177–178, 202
- Interagency Working Group on Neurotoxicology, 19
- International Code of Conduct on the Distribution and Use of Pesticides, 242,243,249-251,253-256
- International Group of National Associations of Manufacturers of Agrochemical Products, 243, 255
- international issues, 21, 56-57
  - effects of U.S. export practices, 242–245
  - monitoring of toxic substances, 132, 134
  - neurotoxicological research, 256-260
  - pesticide residues in domestic and imported food, 241-242
  - regulatory activities, 21–22, 115, 237–256
  - regulatory issues in developing countries, 248–256
  - regulatory policies in other industrialized countries, 245–248
  - testing guidelines, 191
  - U.S. export laws, 239-241
  - U.S. regulation of neurotoxic substances, 239-245
  - see *also* developing countries; exports of toxic substances; imports
- International Neurotoxicology Association, 256,258
- International Program on Chemical Safety, 242
- International Rice Research Institute, 252-253
- ion channels, 7, 66, 72, 118, 295
- Iraq, mercury poisoning in, 47,48,49,243,257
- isopropanol, 179
- Italy
  - research on neurotoxicity, 258, 259
  - researcher training, 259
- Japan
  - human tissue monitoring, 132
  - mercury poisoning in Minamata Bay, 47,48,247, 257
  - regulatory policies in, 247–248, 259
  - research on neurotoxicity, 258, 259
- kainic acid, 124
- Kenya, regulatory issues in, 256
- Kepone, incidents of poisoning, 47,50,293
- Kuhnburg Figure Matching Test, 127
- labeling, 29,44, 169, 171
  - of cosmetics, 28
  - effectiveness of regulatory requirements, 172
  - of exported pesticides, 171, 172, 240, 242–243, 247, 248, 253-255
  - of hazardous substances, 184, 187, 247, 248
  - incidents of poisoning resulting from violations of, 242–243
  - with pictograms, 243–244
  - WHO requirements, 249
- latent effects, 50,54, 70, 107
  - acute delayed neurotoxicity, 118
  - defined, 338
  - of organophosphates, 117–1 18, 194, 199,204,284,290-291, 295
  - and risk assessment, 15, 151–152, 155
  - subchronic delayed neurotoxicity, 118
- lathyrism, 55
- lead
  - in air, 273–274, 276, 281
  - cost-benefit analyses, 20, 216, 230-231,232
  - in drinking water, 8,216, 221,230,231,267,269, 277–279, 281
  - effects on human body, 229–230, 271–273
  - estimates of exposure, nationally, 230
  - Federal regulation of, 8,46, 182, 183
  - in food, 267, 269, 274-275, 281
  - in gasoline, 216,221,230,231,257, 267,269, 273–274, 275, 281
  - health benefits of reducing neurotoxic effects in children, 231, 232
  - in incinerator ash, 279–280
  - levels of exposure, 270-271,274,281
  - MCLs, 183
  - monitoring programs, 133, 134
  - neurological effects of, 6,8,46,56,72-73,74, 150, 162, 181, 185
  - occupational exposures, 269,276
  - OSHA health standards, 185
  - in paint, 8, 184, 189–191, 257, 267–269, 276-277
  - PELs, 276
  - in pesticides, 274
  - regulatory activity, 211,213, 267, 273–281
  - research on toxicity, 256-257, 258, 259

- risk assessment approaches, 150, 151
- routes of exposure, 269
- screening method for humans, 270
- sites of accumulation in the body, 64
- in soil, 269, 280-281
- sources of exposure, 8, 267, 46, 267-269, 273
- standard setting, 181-181, 184, 189, 276, 277, 281
- threshold for, 162, 267, 270-271, 281
- water quality standards, 183, 281
- see *also* lead poisoning
- Gad-Based Paint Poisoning Prevention Act (LBPPPA)
  - amendments, 189, 190
  - control measures under, 187, 189-191, 276-277, 280
  - regulatory authority, 16, 161
  - risk assessment approach, 161
  - toxic substances regulated by, 161
- Lead Industries Association, Inc., 162, 182 n.8
- lead poisoning, 45, 115
  - case studies, 267-281
  - chelation treatment, 271-272
  - in children, 7, 8, 46, 70, 72-73, 155, 181, 184, 229, 260, 267, 268-271, 273, 275, 276, 281
  - cognitive development and, 7, 8, 44, 46, 70, 73, 155, 273
  - costs of, 229-230
  - duration of exposure and, 44, 270-271
  - economic status and, 271
  - historical perspective on, 268
  - incidents of, 47
  - mortality from, 271-272
  - prevalence of, 267, 268
  - prevention of, 8, 189-190, 277, 278, 280, 281
  - research on, 260
  - sources of, 256-157
- learning disorders, 46, 70, 181, 230, 283, 293
  - tests of, 193
- legal issues
  - challenges to EPA standard-setting authority, 162
  - in human testing and monitoring, 130
  - labeling requirements, 172
- legislation
  - diversity of, 159, 211, 213
  - export, 237-241
  - interpreting language of, 162
  - key features of laws regulating toxic substances, 160-161
  - major statutes, 23; see *also specific statutes*
  - see *also* control-oriented measures; licensing and registration; regulations and regulatory issues; standards and standard setting
- leptophos, incidents of poisoning, 47
- levodopa, 72
- licensing and registration
  - application and review processes, 161, 163
  - chemicals, 161, 174-180
  - of color additives, 164-166
  - of cosmetics, 168
  - of drugs and biologics, 29, 161, 166-169
  - environmental contaminants of food, 163-164
  - features of laws, 159-160
  - under Federal Food, Drug, and Cosmetic Act, 29, 161, 163-169, 194, 218
  - under Federal Insecticide, Fungicide, and Rodenticide Act, 161, 168, 170-173, 194, 218
  - of food additives, 161, 164-166
  - implementation of, 159
  - neurotoxicity testing for, 161, 163
  - of pesticides, 164, 161, 170-173
  - regulatory approach, 16, 159
  - risk-benefit analyses, 216
  - under Toxic Substances Control Act, 173-180, 194
- lindane, 183, 250, 252, 292
- lipophilicity of chemicals, 44, 64, 298, 338
- locus ceruleus, 67
- Lou Gehrig's disease, 54, 70
- LSD, 51, 74
- Lucel-7, 47, 55-56, 73
- malathion, 251, 284
- Malaysia, regulatory issues in, 250-252
- manganese, 47, 48, 257
- manganese madness, 48
- mania, 71
- margin of safety, 338
  - EPA interpretation, 180-181
  - risk assessment approaches, 149, 162
- marijuana, 10, 53
- Marine Protection, Research, and Sanctuaries Act (MPRSA)
  - control measures under, 187, 188-189
  - regulatory authority, 16, 23, 161
  - risk assessment approach, 161
  - toxic substances regulated by, 161
- Maternal and Child Health Services Block Grant, 277, 280
- maximum contaminant levels (MCLs) and maximum contaminant level goals (MCLGs), 183, 198, 278-279, 338
- MDMA, effects on nervous system, 9, 51-52
- mental disorders
  - in children 45, 70
  - costs of, 20, 229
  - exacerbation of, 71
  - retardation, 70, 73, 272
- mepheridine, 51, 106
- 2-mercaptobenzothiazole, 179
- mercury
  - delayed effects of, 152
  - effects on nervous system, 72, 74
  - emission standards, 182
  - incidents of poisoning, 45, 46, 49, 131, 247, 257
  - MCLs, 183
  - monitoring programs, 133
  - ocean dumping restrictions, 189
  - OSHA exposure limit, 131
  - research on toxicity, 257
  - routes of exposure, 131
  - symptoms of exposure, 48, 49, 131
  - testing for, 124
  - and water quality standards, 183
- mescaline, 74
- methadone, 115
- methanol, 14, 136, 186-187, 203
- methomyl, 284
- methoxychlor, 183
- methyl alcohol, 296, 297
- methyl bromide, 255, 294
- methyl chloride, 166

- methyl chloroform, 303  
 methyl ethyl ketone, 14, 136  
 methyl ethyl ketoxime, 179  
 methyl tin, 166  
 methyl-n-butyl ketone, 299  
   incidents of poisoning, 47, 49  
   releases of, 14, 136  
   route of exposure to, 108  
 2-methyl-4-chlorophenoxyacetic acid, 294  
 methyl-tert-butyl ether, 179  
 methylcyclohexane, 299  
 methylcyclopentane, 299  
 methylene chloride, 296, 298  
 methylmercury, 15, 48, 49, 115, 152, 243, 257, 258  
 mevinphos, 284  
 Mexico  
   pesticide import problems, 243  
   regulatory issues in, 254-255  
   research on neurotoxicity, 258  
 MicroTox System, 128  
 Milan Automated Neurobehavioral System, 127  
 Minamata Bay, Japan, methylmercury poisoning, 47, 48, 247  
 Mine Safety and Health Administration, 161, 185  
 Minerals Management Service, 133  
 Mira Test, 127  
 mirex, 292  
 monitoring toxic substances  
   adequacy of regulatory structure determined through, 203-204  
   animal tissues, 132  
   biological programs, 13, 132, 133-134, 137  
   for cholinesterase inhibition, 84, 287, 289  
   coordination of programs, 325-326  
   FDA postmarked system for adverse drug reactions, 28, 29, 168, 169, 198  
   in human tissues, 132, 137  
   legal and ethical considerations, 130  
   mechanisms, 13, 203-204  
   need for, 13, 30, 289  
   neurophysiological techniques, 128  
   occupational exposures, 13, 30, 131, 133  
   pesticides, 132, 133, 134, 135, 241, 242, 251-255, 289, 296  
   purpose of, 133  
   specimen banking, 132-133, 137  
   worker safety programs, 131  
   see *also* Toxics Release Inventory  
 monoamine oxidase inhibitor, 6, 72  
 monohalomethanes, 123-124  
 mood and personality, effects of neurotoxic substances on, 46, 230, 283, 285  
 morphine, 74  
 mortality  
   abused drugs, 51, 52  
   mercury poisoning, 47, 48, 49  
   motor neuron disease, 54  
   Parkinson's disease, 3, 54, 55  
   from pesticide poisoning, 250, 251, 283, 285  
 motor activity  
   animal tests of, 13, 20, 110, 111-114, 116, 118, 136, 178, 224-225, 226, 231, 338  
   defined, 111-112  
   effects of neurotoxic substances on, 46-50, 53, 72, 109, 117, 118, 123, 131, 271  
   as an indicator of neurotoxicity, 112, 116, 194  
   mechanical recording of, 113  
   observational analysis, 112-113  
   sensory systems and, 70  
   specificity of measures, 114  
   see *also* screening  
 motor neuron disease, 54, 55  
 motor neurons, 66, 70, 74  
 MPTP  
   animal model for experiments, 106  
   effects on nervous system, 51, 54  
   incidents of poisoning, 47, 70  
   and Parkinson's disease, 6, 51, 54, 72  
 multiple sclerosis, 70, 120, 259  
 myelin/myelin sheath  
   aging and, 67  
   assessment of effects of neurotoxic substances on, 124  
   destruction of, 336  
   effects of toxic substances on, 67  
   function of, 65, 66, 338  
   neurotoxic substances acting on, 74  
 myelinopathy, 67  
  
 National Academy of Sciences, 8, 45  
   proposed study by, 27  
   risk assessment recommendations, 146-147  
   testing recommendations of, 114, 116  
 National Aeronautics and Space Administration, research activities of, 9, 11, 92  
 National Agricultural Chemicals Association, 255  
 National Ambient Air Quality Standards, 180-181  
 National Association for Perinatal Addiction Research and Education, 10, 53  
 National Bureau of Standards, monitoring activities, 132  
 National Cancer Institute, 86, 177  
 National Center for Education in Maternal and Child Health, 277  
 National Center for Health Statistics  
   HHANES, 132  
   NHANES II, 132, 230 n.19  
   NHANES III, 132-133  
 National Center for Toxicological Research  
   Collaborative Behavioral Teratology Study, 115  
   research activities of, 12, 88-89,  
 National Consumer Health Information and Health Promotion Act, 190  
 National Emissions Standards for Hazardous Air Pollutants, 181, 182  
 National Environmental Specimen Bank, 132  
 National Food Processors Association, 282  
 National Health and Nutrition Examination Surveys  
   II, 132, 230 n.19  
   III, 132-133  
 National Human Adipose Tissue Survey, 133  
 National Institute on Aging, research activities, 86  
 National Institute of Child Health and Human Development, research activities, 86-87  
 National Institute on Drug Abuse, 9, 53  
   developmental neurotoxicology workshop, 115  
   research activities of, 87-88  
 National Institute of Environmental Health Sciences, 11, 85, 177  
 National Institute of Mental Health, research activities, 88

- National Institute of Neurological Disorders and Stroke, research activities, 11, 84–85
- National Institute for Occupational Safety and Health (NIOSH), 45,56, 177
- Educational Resource Centers, 99-100
  - protective measures recommended by, 30,296
  - research activities of, 12, 34-35, 89–90
  - standard setting by, 28, 185, 186, 198–199
  - testing recommendations, 126
- National Institutes of Health (NIH)
- policy issues and options, 32-33
  - research activities, 9, 11, 32–33, 81, 84-87, 122, 321–322
  - see *also specific institutes and programs*
- National Library of Medicine, research activities, 87
- National Oceanic and Atmospheric Administration, tissue monitoring program, 133
- National Primary Drinking Water Regulations, 183, 191, 278, 338
- National Research Council, 146-147
- National Residue Program, 135
- National Science Foundation, 177
- National Status and Trends Program for Marine Environment Quality, 133
- National Toxicology Program
- in vitro test development, 122
  - research activities, 22, 85–86, 259, 261
- Nationwide Food Consumption Survey, 135
- Natural Resources Defense Council, 282
- naturally occurring toxic substances
- in algae, see saxitoxin
  - in buckthorn, 73–74
  - cassava, 55
  - cycad, 54, 74
  - drought-resistant grass pea, 55
  - effects of, 54-55
  - in puffer fish, see tetrodotoxin
  - scorpion toxin, 72
- neostriatum, 68
- nerve gas, 50, 74
- nervous system
- adult-stage modifications, 67
  - changes with aging, 8, 67
  - development of, 8,67
  - diseases, 54, 229; see *also specific diseases*
  - effects of toxic substances on, 67–71; see *also symptoms of toxicity*
  - immune system interaction with, 71
  - functional changes due to toxic substances, 69–70
  - lesions, 172
  - pesticide effects on, 283-285
  - structural changes due to toxic substances, 67-69, 267
  - structure, 43, 65-67
  - vulnerability to toxic substances, 4, 5, 8, 44
  - see *also central nervous system; peripheral nervous system; and other specific elements of the nervous system*
- Netherlands, pesticide regulation, 249
- neural tube, 67, 70
- neuritic plaques, 67
- Neurobehavioral Evaluation System, 127
- neurobehavioral tests
- advantages and limitations of, 116, 128
  - in animals, 82, 112, 116-117, 171
  - in combination with NTE, 118
  - computer-based, 127–128
  - environmental factors in, 126
  - examiner factors in, 126
  - Finland Institute of Occupational Health approach, 126, 127
  - in humans, 70, 125–126, 137
  - observational, 112
  - psychological testing, 126
  - reproducibility of, 128
  - selection of techniques, 125–126
  - subject factors in, 126
  - World Health Organization approach, 126-127
- neuroblastoma C-1300 cell lines, 124
- neurofibrillary tangles, 67
- neuromuscular disorders, exacerbation of, 70
- neuromuscular junction, 66, 124, 338
- neuronal membrane, 72
- neuronal potentials, 118
- neurons, 124, 338
- anoxia, 67
  - degeneration, 54,72,203,338
  - development of, 67
  - effects of toxic substances on, 9, 67
  - electrical properties, 118
  - loss of, 67,68,74, 107
  - neurotoxic substances acting on, 72–74
  - regeneration, 44, 67
  - retinal, 124
  - structure, 5, 65, 72
- neuropathies
- defined, 67
  - delayed, 204
  - from industrial chemicals, 49, 108
  - mixed, 70, 338
  - peripheral, 181
  - from pesticides, 291–292
- neuropathological examination
- of animals, 13, 110, 111, 114, 116, 118, 136, 172, 178, 194, 224-225
  - in combination with NTE, 118
  - costs of, 20, 224-225, 231
  - defined, 338
  - electrophysiological testing with, 119
  - evaluation of PMN assessment accuracy with, 204
  - FDA policy on, 194
  - with glial fibrillary acidic protein radioimmunoassay, 117
  - with operant behavior studies, 116
  - sensitivity of, 193
- neurophysiological tests, 338
- advantages of, 13, 128, 137
  - in animals, 118–121, 137
  - brainstem auditory evoked responses, 119, 128
  - electromyography and electroneurography, 128
  - EPA research on, 82
  - in humans, 70, 128, 137
  - somatosensory evoked potentials, 120-121, 128
  - visual evoked potentials, 119-120, 128
- neurotoxic esterase assay (NTE), 111, 117–118, 137, 178, 194,339
- neurotoxic substances, 339
- absorption, distribution, biotransformation, and excretion, 64, 108

- additive effects, 44, 64, 65  
behavioral effects, 70  
benefits of regulating, 228-230,232  
classes of, 71-76, 175  
classification criteria, 175  
detectors of, 199  
determinants of toxicity, 7,63  
effects on nervous system, 12, 67-71; see *also* symptoms of neurotoxicity  
evaluation in animals, 109-110  
export policy, 57  
health costs of, 228-230; see *also specific conditions*  
incidents of poisoning, 47 (table)  
lipophilicity of, 44,64  
multiple, interaction of, 64-65  
number of, 3, 4, 43  
releases by industry, 135  
susceptibility to, 70-71  
see *also* abused drugs; chemicals; industrial chemicals; pesticides; therapeutic drugs; *and specific substances*
- neurotoxicology  
defined, 63,339  
developmental, in animals, 114-116  
fundamentals, 63-76  
principles, 63-65  
see *also* health effects
- neurotransmitters  
aging and, 67  
classical, 66, 336  
depletion of, 109  
effects of abused drugs on, 51, 52, 74, 74  
functions of, 65,66,339  
hippocampal, 71  
inhibition of, 6, 7, 67  
neuropeptides, 66, 74  
see *also specific neurotransmitters*
- nicotine, 74  
nitrogen oxides, 181, 182, 258  
no observed adverse effect levels (NOAELs), 106, 146  
defined, 147, 339  
in dose-response assessment, 147-148, 153  
in risk assessment, 147-149, 150-151  
in standard setting, 187  
techniques to determine, 114, 115, 118, 147  
no observed effect levels (NOELs)  
defined, 147, 339  
in dose-response assessment, 147-148, 153  
norepinephrine, 66, 74, 109  
notification of unreasonable risk, 218  
nurses, education of, 98-99  
nutritional status, and toxicity, 70, 71, 108, 269
- occupational exposures, 148  
administrative controls, 336  
to carbon disulfide, 256  
epidemiological studies, 26, 128-129  
ethical issues, 130, 131  
at fabric production plant, 47, 49  
Hopewell, Virginia, chemical plant workers, 50,293  
incidence of disease from, 125  
to lead, 257, 269,276  
mercury removal from thermometers, 131  
monitoring, 13, 133, 289  
to organic solvents, 30, 257, 296-304  
to pesticides, 45, 50, 267, 281-285, 289, 293, 294; see *also* pesticide poisonings  
at plastic manufacturing plant, 47, 55-56  
prevention of, 130-131,267,336  
regulation of, 16; see *also* Occupational Safety and Health Act  
research on, 256  
vulnerability of workers, 9  
Occupational Safety and Health Act, 56  
exposure limit for mercury, 131  
general duty clause, 302  
MCL for lead in air, 278  
protection of farmworkers under, 26,250-252,267,284,285, 288-289  
regulatory authority, 16, 161  
reporting requirements for adverse effects, 204  
risk assessment approach, 161  
standard setting under, 16, 28, 180, 185-187, 195, 267, 276  
toxic substances regulated by, 161  
Occupational Safety and Health Administration (OSHA), 177  
adequacy of efforts of, 28, 30  
economic analysis requirements, 303  
enforcement of regulations, 30, 276  
Hazard Communication Right-to-Know Standard, 285  
permissible exposure limits, 185-187, 199,203,302-304  
policy issues and options for, 28-30  
regulatory authority of, 15-16, 28, 161, 185, 302  
risk assessment applications, 150, 151, 216  
occupational safety and health programs, 130  
octadecyl phosphite, 166  
Office of Management and Budget, 11,84, 159, 162,214,231  
oleylamine, 179  
Omnibus Budget Reconciliation Act, 277  
operant behavior  
defined, 116  
schedule-controlled tests, 13, 110, 111, 116-117, 136, 137, 178, 192, 224-225, 231,340  
optic neuritis, 120, 272  
organ cultures, defined, 123, 339  
organic farming, 291  
organic solvents, 6, 339  
classes of, 296, 297  
effects of, 30, 119, 267, 296, 298-300  
encephalopathy from, 299-300  
inhalant abuse, 296  
labeling of, 184  
occupational exposures, 30, 257, 296-304  
OSHA regulations, 267,302-303  
PELs, 302-304  
protection of workers from, 267,296,300-302  
research on toxicity of, 256-259, 260  
risk from, 48  
route of exposure to, 108, 296, 298  
testing for, 119, 126  
uptake, distribution, and elimination of, 298  
volume of production in U. S., **296**  
**see also specific solvents**
- Organochlorine* insecticides, 49, 292-294  
organoleptic effects, 182-183, 339  
organophosphites, 166  
organophosphorous pesticides, 292-293, 339

- action on nervous system, 26, 50, 74,290
- animal tests for, 13, 106-107, 110, 117-1 18, 136-137, 171, 194,290
- delayed effects, 117-118, 194, 199,204,284,290-291, 295
- duration of exposure and toxicity, 44,67, 107
- effects on nervous system, 6, 26, 49-50, 67, 73, 107, 117, 290-292,294,295
- ethyl-p-nitrophenyl phosphonothionate, 150, 151
- extent of testing of, 18, 171, 199, 204
- in vitro tests of, 124
- incidents of toxicity, 47,69, 284; see *also* pesticide poisoning
- list of, by level of toxicity, 292-293
- monitoring of exposures to, 134, 289
- reentry intervals for farmworkers, 287
- research needs on, 26, 284
- study design for, 178
- organotin, 47, 74, 257
- ozone, 181
  
- paint
  - fumes, toxicity of, 4,44,296
  - lead in, 8, 184, 189-191,257,267-269, 276-277
- Papua New Guinea, pesticide import violations, 243,251
- paralytic shellfish poisoning, 72
- paraquat, 250,251
- parathion, 255,284,288
- Parkinson's disease
  - environmental cause, 3, 54-55, 70, 108
  - mortality, 3, 55
  - MPTP as cause of, 3,51,54,72
  - research on, 259
- particulate matter, 181, 182
- pattern reversal evoked potentials, 119, 120, 128
- pentachlorophenol, 250
- People's Republic of China research on neurotoxicity, 22,258, 260
- perhexilline maleate, 74
- peripheral nervous system
  - damage from pesticides, 291-292
  - function tests, 178
  - structure, 66, 339
  - vulnerability of, 73
- permissible exposure limits (PELs), 28,30, 185-187, 199,203, 276,296,302-304,339
- personality effects, see mood and personality
- pest control, new approaches, 243,290,295,337
- Pesticide Action Network, Dirty Dozen Campaign, 249-250
- pesticide poisoning
  - and accidents, 285
  - Agent Orange, 295
  - of agricultural workers, 45, 50,267, 282-285, 288,289,294, 295
  - Bhopal, India, accident, 243
  - case studies of, 281-296
  - in children, 283, 284, 293
  - chlordecone (Kepone) in Hopewell, Virginia 47, 50, 293
  - container recycling and, 251
  - deaths from, 250,251,283,285,290, 294,295
  - in developing countries, 250, 260
  - diagnosis of, 50,289
  - dose and, 283,290-292,294
  - effects on nervous system, **6, 26, 49-50, 67, 73, 107, 117,** 283-285,290-295
  - epidemiological studies of, 285,295
  - exposure route and, 283, 292-293
  - labeling violations and, 242-243,251
  - Lake Volta, Ghana, incident, 243,251
  - major incidents of, 47 (table)
  - mercury fungicides, 47-49
  - from methyl bromide, 294
  - from misuse in developing countries, 50,239,248-249,251, 252,253
  - monitoring of, 251-256, 289, 296
  - from organochlorines, 293
  - from organophosphates, 47,50,69,284,290-292
  - prevalence of, 248-249,252,283,284, 295
  - prevention of, 26,28,30,250-252,267, 284,286-289,295
  - recovery periods, 284, 290
  - reentry intervals and, 288
  - repackaging and, 243, 247,248, 251
  - reporting of illnesses related to, 50, 283, 289,295
- pesticides, 339
  - active ingredients, 336
  - in adipose tissue, 133, 292-293
  - advertising, 251, 255-256
  - alternatives to use of, 243,290-291,295
  - banned, restricted, or unregistered, 21-22,173,237-238,240, 242, 249-250, 252, 253, 255, 261, 283, 288, 290, 292-295; see *also* Exports
  - Belgian regulatory policies, 246-247
  - Canadian regulatory policies, 245
  - cancellation/suspension of registration, 173
  - chlorophenoxy herbicides, 294-295
  - cholinesterase inhibitors, 290-292
  - data call-ins, 172, 173,203
  - defined, 49,281-282
  - detection of residues, 50
  - development, 225-226, 231-232
  - in developing countries, regulatory issues, 248-256, 260; see *also* exports of toxic substances; *and specific countries*
  - dioxin contamination of, 294
  - Experimental Use Permit, 170-171,337
  - exports of, 56-57, 237, 241-245
  - Federal Republic of Germany regulatory policies, 245-246
  - fishing with, 252
  - fumigants, 293-294
  - inert ingredients, neurotoxicity evaluations, 24, 288
  - innovation in, and neurotoxicity testing, 226-227
  - International Code of Conduct on the Distribution and Use of Pesticides, 242,243
  - international effects of U.S. export practices, 242-245
  - Japanese regulatory policies, 247-248
  - labeling, 171, 172,240,242-243,247, 248,253-255
  - market size worldwide, 237
  - MCLs for, 183
  - me-too registration, 240, 253,255,338
  - monitoring of, 132, 133, 134, 135, 241, 242, 251, 253-255, 289
  - neurotoxic, 43, 172, 183, 290-295
  - notification requirements, 22, 239-240, 247, 261, 290, 339
  - occupational exposures to, 281-283
  - organochlorine, 292-293
  - prior informed consent, 249,339
  - protective clothing, 250,283,287-289

- pyrethroids, 72,295
- reentry intervals for farmworkers, 284, 286-288, 290, 295-296,340
- registered, 3,43,49, 195,237
- registration of new compounds, 17, 161, 170-171, 197, 199, 216,241,287-288,295
- regulation of (Federal), 16, 17, 56, 164, 170-173, 204, 285-289
- reregistration of existing compounds, 17, 171-173, 197, 241, 286,287
- research on neurotoxicity, 256, 257-258, 295
- residues in domestic and imported food, 241-242, 251, 282
- resistance of pests to, 243
- risk standards, 25, 168, 241
- risk-benefit analysis, 216, 217,296
- safety information, 287
- safety, measure of, 221-222
- special review of, 173, 197, 216
- state regulation of, 289-290
- testing for neurotoxicity, 17,18,115,119,170-173, 191-192, 194, 199,204,287,295
- Tolerance Assessment System, 135
- tolerances, 27, 164, 168, 171,216, 241,247, 254, 341
- use annually, 282, 295
- WHO toxicity classification, 249, 254
- see *also* carbamate insecticides; organophosphorous pesticides
- phencyclidine, 9,52,71
- phenylene diamines (unsubstituted), 179
- Philippines
- pesticide problems in, 251
- regulatory issues in, 252-253
- phosalone, 284
- Phosdrin, ,242,284
- phosphamidon, 284
- phosphines, 175
- Phosvel, incidents of poisoning, 47
- photoreceptor cells, 124
- physicians, education of, 98
- Poison Prevention Packaging Act (PPPA)
- control measures under, 187, 190-191
- regulatory authority, 16, 161
- risk assessment approach, 161
- standard setting under, 180
- toxic substances regulated by, 161
- policy issues and options
- for ADAMHA, 33
- adequacy of regulatory framework, 23-31
- adequacy of research framework, 31-35
- confidential business information, 25
- cosmetics testing, 28
- for CPSC, 31
- education and training of research and health-care professionals, 36
- education of workers and public, 37-38
- for EPA, 23-27,31-32
- for FDA, 27-28,33-34
- interagency coordination of research and regulatory programs, **35-36**
- international regulatory and research programs, 38-40
- Material Safety Data Sheets, 30
- monitoring of adverse health effects, 28, 30
- neurotoxicity testing requirements, 24-25, 27-28
- for NIH, 32-33
- for NIOSH, 34-35
- for OSHA, 28,30
- protection of agricultural workers, 26,28,30
- statutory scope of neurotoxicity regulation, 26-27
- polyaromatic hydrocarbons, 133
- polychlorinated biphenyls (PCBs), 115, 180
- incidents of poisoning, 47, 247
- monitoring of, 133, 134
- research on, 258
- potentiation, 65,339
- Poultry Products Inspection Act, 241,242
- premanufacture notices, 17, 174-176, 194, 196, 197,201-202, 219-220,227,247
- prevention of exposure
- adequacy of measures, 28, 30, 288, 289
- educational programs, 30, 130
- engineering controls, 13, 30, 267, 276,296, 300, 301, 337
- to lead, 8, 189-190, 277, 278,281
- medical controls, 130-131, 300
- to organic solvents, 30, 296, 300-302
- to pesticides, 26,250-252,267,284, 285-290, 295,340
- protective clothing and devices, 30, 250, 267, 283, 286, 288-289,295,296,300-302, 339
- reentry levels for farmworkers, 284,286, 288, 290, 295, 340
- state programs, 289-290
- training in handling of pesticides, 252,255,290
- in workplace, 130-131, 300-302, 336
- see *also* monitoring toxic substances
- propylene, 14, 136
- protective clothing and devices, 30, 250, 267, 283, 286, 288-289,295,296,300-302, 339
- psilocybin, 74
- psycho organic syndrome, 296
- psychoactive drugs, 6, 10,27,44,50
- psychological testing, 126
- psychosis, 71
- Public Health Service Act, 167
- Purkinje cells, 67
- pyramidal cells, 68
- pyrethroid pesticides, 72,295
- pyridine derivatives, 175
- quaternary ammonium compounds, 175
- quinone, 179
- radionuclides, 182
- rat glioma C-6 cell lines, 124
- reentry levels for farmworkers, 284, 286, 288, 290, 295, 340
- reference dose (RfD), 116, 148-149, 150, 153, 340
- registration, see licensing and registration
- regulations and regulatory issues
- adequacy of regulatory framework, 201-203
- administration of laws, 56, 160-161; see *also specific agencies*
- application and notification procedures, 159; see *also* licensing and registration
- in behavioral teratology, 115
- consistency of protection, 17, 19, 194-196, 199-200
- consistency of requirements, 16-17, 194
- coordination and cooperation among agencies, 19, 176, 194,

- 198-199,200-201,205, 326-327  
 costs of compliance, 20, 201, 211, 215, 217-218, 220, 230  
 diversity of, 159  
 economic benefits of, 228-230  
 economic impacts of, 213-215  
 economic incentives, 161  
 effectiveness of regulatory programs, 203-204, 205,274,281  
 endpoint basis for, 56  
 expected and detected neurotoxicity, 201-203  
 expenditures by government, 215  
 export laws, 239-241  
 general toxicological considerations in, 194-199  
 of human research, 130  
 impact analyses, 211 n.1, 214, 220, 231  
 of industrial chemicals, 56  
 in industrialized countries, 245-248  
 international regulatory activities, 21-22, 115, 237-256  
 labeling, 172  
 for lead, 46, 273-281  
 measurements of effectiveness, 201  
 minimal data set, value of, 201  
 neurological considerations in, 18-19, 178, 199-201, 204  
 new initiatives, 191-194  
 new v. existing chemicals, 18, 196-198  
 nonregulatory factors affecting implementation, 159, 161, 162  
 for pesticides, 241-242,286-290  
 redundancy of effort among agencies, 198  
 risk assessment approaches, 146, 150-151  
 State regulation of lead, 277, 278  
 State regulation of pesticides, 289-290  
 statutory authority, 56; see *also* legislation; *and specific statutes*  
 tolerance setting, 164  
 see *also* cost-benefit analysis; economic issues  
 regulatory analyses, 20, 211, 218 n.11  
 institutionalization of, 215, 230  
 utility in regulatory policymaking, 220-221  
 regulatory impact analyses (RIAs), 211 n.1, 214, 216, 231  
 reporting of harmful effects, 180, 197  
 CPSA requirements, 204  
 FFDC requirements, 167,203  
 OSH Act requirements, 204  
 pesticide poisoning, 50,283,289,295  
 of therapeutic drugs, 18, 167, 203  
 research  
 academic activities, 92-94, 256-259  
 adequacy of Federal programs, 31-35, 81  
 by charitable organizations, 97  
 under Clean Air Act, 180  
 comparison of U.S. and foreign programs, 259  
 coordination of Federal programs, 200, 325  
 development of methodologies, 81,259  
 Federal activities, 9, 11-12, 81-92, 321-324; see *also specific agencies*  
 funding, 9, 11-12, 81, 82-84,259  
 industry activities, 12, 94-95, 256-259  
 interactions among, government, academia, and industry, 96, 256-259  
 international efforts, 22, 256-260, 261  
 journals, 22,256  
 leadership roles by foreign governments, 260  
 needs, 3, 11,26,55,76, 137, 154--155, 259-260, 295  
 pathological changes related to functional impairment, 154  
 resources, 259  
 trends internationally, 21,258-259,261  
 workplace, 129; see *also* occupational exposures  
 see *also* academic research; epidemiological studies; industrial research  
 research scientists, education of, 12, 97, 259  
 Resource Conservation and Recovery Act (RCRA), 135, 176  
 control measures under, 187, 189-191  
 export controls, 239, 240  
 regulatory authority, 16, 23, 161  
 risk assessment approach, 161  
 toxic substances regulated by, 161  
 Restoril, 29, 169  
 risk  
 acceptable, 13, 145, 146, 164, 196, 340  
 characterization of, 148-149  
 defined, 13  
 and economic benefit, 216-217  
 expression of, 13, 145  
 individual v. societal, 154, 155  
 negligible, 168  
 public perceptions of, 145-146  
 and stringency of evaluation process, 17, 195-196  
 unreasonable, 212, 241  
 vulnerable populations, 8-9, 45  
 zero, 153, 168, 339  
 risk assessment  
 for acrylamide exposures, 150, 151,216  
 approaches for neurotoxic substances, 56, 150-154, 160-161  
 carcinogen approach, 15, 149, 150, 151, 152, 153  
 characterization of risk, 56, 105, 106, 148-149, 150, 154; see *also* testing  
 components of, 145, 231  
 controversial issues in, 14-15, 146  
 coordination of programs, 326-327  
 defined, 13, 145,211,340  
 dose-response relationship, 147-148, 153-154  
 EPA guidelines, 116, 146, 150, 192  
 exposure assessment, 148  
 hazard identification, 147, 148, 152, 154  
 Integrated Risk Information System, 198  
 and latent adverse effects, 15, 151-152, 155  
 limitations of current approaches, 106, 151-152  
 MOS/MOE approaches, 149, 162, 181  
 regulatory approaches, 17, 25, 146, 150-151, 160-161  
 safety factors, 148-149, 153-154  
 uncertainty in, 149, 153, 154, 340, 341  
 risk-benefit analysis, 211, 216-217, 218 n.11, 286, 296, 340  
 risk management  
 defined, 13, 145,211,340  
 process of, 145, 149-150  
 purpose of, 149  
 risk balancing approach, 149-150  
 risk only approach, 149  
 technological control approach, 150  
 Rorschach Inkblot Test, 127  
 Safe Drinking Water Act (SDWA), 26  
 1986 amendments, 183  
 cost-benefit analysis under, 216



- regulatory authority, 16, 23, 160
- risk assessment approach, 160
- standard setting under, 180, 183–184, 278
- toxic substances regulated by, 160
- Santa Ana Dexterity Test, 127
- saxitoxin, 72
- Scandinavian counties
  - neurotoxicological research, 22, 256-259, 260,261
  - regulatory policies in, 260, 261
  - researcher training, 259
- schedule-controlled operant behavior (SCOB) tests, 13, 110, 111, 116-117, 136, 137, 178, 192,224-225,231,340
- scorpion toxin, 72
- screening, 154, 340
  - adequacy of, for chemicals, 17
  - developmental neurotoxicity, 116
  - computer-assisted, **82, 175**
  - in EPA core test battery, 111
  - FDA policy on, 194
  - with functional observational battery, 82, 111, 112, 193
  - with in vitro tests, 13, 110, 136
  - for lead exposure, 270,277,278,280,281
  - with motor activity test, 82, 193
  - of pesticides, 199, 204
  - structure-activity relationships, 18, 175, 194, 203, 340
  - WHO Neurobehavioral Core Test Battery, 126-127
- secleron, 251
- Senegal, pesticide import violations, 243,251
- sensory systems
  - effects of neurotoxic substances on, 46, 51–52, 272
  - evoked potentials, 118–119, 128, 337
  - functions of, 66
  - and motor functions, 70
  - neuron losses, 74
- serotonin, 66
  - effects of abused drugs on, 9, 51–52, 74
- short-term exposure limits, 302
- significant new use rule, 174
- silicon, and Alzheimer's disease, 54–55
- silver, 133
- soil, lead in, 269, 280-281
- solvents, see organic solvents
- somatosensory evoked potentials, 119, 120–121, 128
- South Korea, pesticide import problems, 243
- Soviet Union, neurotoxicity research, 22,258,260
- specimen banking
  - domestic and international programs, 132-133
  - nonhuman tissues, 133
- spina bifida, 70
- spinal cord
  - clioquinol effects on, 74
  - damage from pesticides, 291-292
  - degeneration, 55
  - development of, 67
  - functions, 66
- standards and standard setting
  - action levels for contaminants in foods, 164, 241–242, 336
  - air quality, 180-181
  - for airborne contaminants, 181, 182, 185
  - carcinogenicity -based, 185
  - challenges to EPA authority, 162, 182 n.8
  - under Clean Air Act, 180-182
  - under Clean Water Act, 182–183
  - under Consumer Product Safety Act, 184
  - cost-benefit analysis, 181
  - drinking water, 183-184
  - economic considerations in, 199
  - emissions, 181, 182
  - exposure probability and, 195
  - features of laws, 159, 160-161
  - under Federal Hazardous Substances Act, 184
  - under Federal Mine Safety and Health Act, 185
  - under Federal Water Pollution Control Act, 182–183
  - hazard communication, 187
  - by international groups, 242
  - for lead, 271,276,278-279
  - litigation over validity of, 276
  - margin of safety in, 180-181, 338
  - maximum contaminant levels and maximum contaminant level goals, 183, 198,278-279,338
  - neurotoxicity considered in, 162
  - under Occupational Safety and Health Act, 185–187
  - for packaging, 190
  - permissible daily intakes, 189
  - permissible exposure limits, 28,30, 185-187, 199,203,276, 296,302-304,339
  - for pesticide residues, 164
  - recommended exposure limits, 199, 302–303, 340
  - reentry intervals for farmworkers, 284, 286-288, 340
  - regulatory approach, 16, 159, 180
  - regulatory impact analysis, 181
  - reportable quantities, 187
  - under Safe Drinking Water Act, 183–184, 191
  - threshold limit values, 151, 185, 186, 199,203,341
  - and toxicity testing requirements, 180
  - water quality, 182
  - see also regulations and regulatory issues; *and specific statutes*
- steroids, 70
- stroke research, 259
- structure-activity relationships, 17, 18, 25, 175, 194, 203, 340
- styrene, 14, 136, 258, 299, 303
- substance P, 66
- substantia nigra, 6, 67, 72
- Sudan, pesticide poisoning in, 251
- sudden infant death syndrome, 10,53
- sulfur oxides, 181
- sulfuric acid, 14, 136
- sulfuryl fluoride, 120
- Superfund Amendments and Reauthorization Act, 135
  - confidentiality under, 176
  - health effects contemplated by, 188
  - regulatory authority, 161
  - research authorized by, 188
  - risk assessment approach, 161
  - toxic substances regulated by, 161, 198
- Sweden
  - human tissue monitoring, 132
  - Performance Evaluation System, 127
- synapse, 66, 70
  - chemical communication at, 66
  - defined, 340
  - measurement of function at endings, 118, 124
- synaptic cleft, 66, 340

- synergism, 64, 65, 340
- 2,4,5-T, 250,294,295
- 2,4,5-TP, 183
- tardive dyskinesia, 6, 44
- TCDD, 294
- Telone II, incidents of poisoning, 47
- temik, 251
- temperature, and toxicity, 109
- testing
- accuracy of PMN assessments, 204
  - computerized/automated techniques, 112–113
  - confidentiality issues in, 19, 176, 202, 218, 226
  - consent decrees for, 177, 197, 201, 202, 336
  - coordination of programs, 325–326
  - of cosmetics, 52, 54, 168, 196
  - criteria, 152
  - cross-species comparisons, 115–116
  - current extent of, 12, 16, 43, 52, 55, 56, 76, 151, 211
  - design, factors considered in, 105–109, 178, 199–200
  - in developing countries, 251–252
  - disincentives to, 174–175, 176
  - economic impacts of, 218; see *also* Costs of testing
  - endpoints, 109, 116, 125, 150, 152, 178
  - EPA guidelines, 110–112, 114–118, 136, 137, 191–193
  - of exports, 240
  - extrapolation of results to other populations, 147, 153
  - FDA requirements, 163, 165–167, 192–194, 199
  - FIFRA guidelines, 115
  - flexibility in, 193, 200
  - of food additives, 52, 192–194
  - in industrialized countries (other than U.S.), 245, 246, 247–248
  - and innovation in drugs and pesticides, 226–227
  - interpretation of safety, 165
  - laboratory automation, 223
  - laboratory capabilities, 223
  - limitations of current tests, 122, 151–152
  - needs, identification of, 324
  - options for changes in requirements for, 24–25
  - personnel, 223
  - protocol requirements, 222
  - quality assurance, 222–223
  - reliability and sensitivity, 26, 115, 152, 191, 193
  - research on new methods, 81–84
  - standardization of, 324–325
  - statutory authority for, 159
  - stringency of, 17, 195–196
  - tiered approach, 18, 109–110, 154, 193, 200, 341
  - triggers for, 24
  - validation, 109, 111, 123–124, 168
  - WHO objectives, 106
  - see *also* animal tests; in vitro tests; human testing and studies; risk assessment; screening
- tetrachloroethylene, 14, 136
- tetraethyl lead, incidents of poisoning, 47, 303
- tetrodotoxin, 45, 72
- Texas Agricultural Hazard Communication Law, 290
- Thailand, pesticide misuse in, 243, 251
- thalidomide, 73
- thallium
- effects on nervous system, 74
  - incidents of poisoning, 47
  - testing of, 124
  - toxicity, 48
  - water quality standards, 183
- therapeutic drugs and biologics
- adverse effects of, 29, 45, 50–51, 167–169
  - for animals, 166, 167
  - benefits assessment, 216
  - benzodiazepine hypnotics, 29, 169
  - efficacy and effectiveness, 217
  - interactions, 8, 29, 45, 169
  - investigational new drugs, 167–168, 203, 338
  - labeling, 29, 169
  - licensing and registration of, 18, 29, 161, 166–169
  - monitoring reactions to, 29, 168, 169
  - neuroeffective substances, 168
  - neurotoxic potential, 3, 45
  - new drug applications, 166, 167, 188, 339
  - packaging information on adverse effects, 28
  - R&D studies, 219
  - reporting of adverse reactions, 18, 167, 203
  - research on neurotoxicity, 258
  - risk assessment, 146, 151, 153
  - risk-benefit analysis, 217
  - safety, measure of, 221–222
  - seizure medication, 44
  - standard for approval, 166–167
  - testing of, 17, 18, 26, 29, 105, 115, 166–168, 169, 199, 204
  - see *also specific drugs*
- thiamine deficiency, 71
- thiocarbamates, 172
- threshold limit values, 151, 185, 186, 199, 203, 341, 302–303
- time-weighted average limits, 302
- tin, 133
- tissue culture
- antibiotics added to, 123
  - applications in neurotoxicology, 122
  - defined, 122, 340
  - embryo, 123–124
  - expenditures for development of methods, 122
  - explants, 124, 337
  - organotypic, 124, 339
  - see *also* Cell culture; Organ culture
- TOCP, incidents of poisoning, 47
- tolerance levels
- for contaminants in foods, 164
  - enforcement of, 241–242
  - lead in canned evaporated milk, 274–275
  - for pesticides residues, 27, 164, 171, 216, 239, 241
  - recommended approach, 27
- toluene, 14, 119, 136, 183, 296, 299, 303
- Total Diet Study, 135
- toxaphene, 183, 250, 255, 292
- toxic substances
- general considerations in regulation of, 194–199
  - see *also* neurotoxic substances
- Toxic Substances Control Act (TSCA), 56, 110
- confidential business information under, 19, 25, 176, 202, 218, 226
  - consent decrees, 17, 177, 179, 197, 201, 202, 336
  - coordination of FIFRA neurotoxicity evaluations with, 191–192

- economic balancing provisions of, 212, 216, 217–218
- existing chemicals, 175, 177–180
- export controls, 21–22, 239–240, 261
- extent of testing under, 17, 18–19, 24–25, 201–202, 204
- licensing and registration under, 16, 161, 173–180, 194, 195, 197
- new chemicals, 174–175
- notification requirement, 218, 239–240
- premanufacture notices, 17, 174–176, 194, 196, 197, 201–202, 203–204, 215, 219–220, 227
- regulatory authority, 16, 20, 160, 213
- risk assessment approach, 160, 196
- significant new use rule, 174
- substances regulated by, 160
- test guidelines, 150, 191, 199, 224
- test rules, 17, 82, 197, 178, 179, 215, 217, 222, 340–341
- Toxics Release Inventory, 13, 14, 17, 43, 122, 134–136, 197
- triadimefon, 113
- triazophos, 292
- tributyl phosphorotrithioates, 173
- 1,1,1-trichloroethane
  - releases of, 14, 136
  - testing of, 115, 135, 179
- trichloroethylene, 14, 136, 299, 303
- 2,4,5-trichlorophenoxypropionic acid, 294
- triethylene glycol monomethyl ethers, testing guidelines, 115, 179
- trimethyl benzenes, 179
- trihalomethanes, 183
- trimethyltin
  - biochemical markers for, 117
  - poisoning, 6, 44, 68, 74
- triorthocresyl phosphate, 47, 69
- triphenyltin, 113
- Tris phosphite, 166
- United Kingdom
  - regulatory policies in, 248
- research on neurotoxicity, 21, 256, 258, 259, 261
- United Nations
  - Food and Agriculture Organization, 135, 242, 243, 249–251, 253–256
  - OECD toxicity testing guidelines, 191, 194
- urea-formaldehyde resins, 179
- U.S. Public Health Service, 189
- vasopressin, 66
- vincristine, 73
- vinyl chloride, 182
- visual evoked potentials, 119–120
- visual systems
  - impairment of, 26, 48, 49, 51, 55, 72, 74, 131, 135, 181
  - substances affecting, 48, 49, 51, 55, 72, 74, 119
  - testing of, 119
- vitamins, toxicity, 6, 44, 74
- Walsh-Healy Act, 185, 186
- water quality standards, 182–183
- Wechsler Adult Intelligence Scale, 127
- Wechsler Memory Scale, 127
- World Health Organization, 22, 135, 242, 255
  - acceptable levels of lead, 271
  - childhood lead intoxication study, 257, 261
  - epidemiological study of dementia, 259
  - objectives of neurotoxicology testing, 106
  - Neurobehavioral Core Test Battery, 126–128
  - organic solvent studies, 257
  - pesticide toxicity classification, 249, 254
  - specimen banking program, 133
  - testing recommendations of, 114, 115, 116, 150
- X-irradiation, 115
- xylene, 14, 136, 299, 303
- zinc pyridinethionine, 108
- Zolone, 284